Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

COVID-PACT RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
191/191 suggested
  • suggested 44 % decrease in Major thrombotic events or death (PE) with a moderate degree of certainty due to some concern in risk of bias
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
  NCT02735707		 RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
591/616 inconclusive
  • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
  NCT02735707		 RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
591/616 inconclusive
  • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons